Evidence map›Paper›PMID 40688242›Full record

ArticleHIV/AIDS (Auckland, N.Z.)2025

Spectrum and Correlates of Dyslipidemia in People Living with HIV on Dolutegravir-Based Regimen Attending Kabutare Hospital, Southern Rwanda: A Cross-Sectional Study.

Honore Nsengumuremyi, Vedaste Nsanzimana, Herbert Tendayi Mapira, Elizabeth Gori, Cuthbert Musarurwa

Abstract read
In one paragraph

Article in HIV/AIDS (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Honore NsengumuremyiDepartment of Biomedical Laboratory Sciences, School of Health Sciences, College of Medicine and Health Sciences, University of Rwanda, Kigali, 3286, Rwanda.ORCID 0009-0002-9539-8471
Vedaste NsanzimanaDepartment of Biomedical Laboratory Sciences, School of Health Sciences, College of Medicine and Health Sciences, University of Rwanda, Kigali, 3286, Rwanda.ORCID 0009-0004-1264-7466
Herbert Tendayi MapiraDepartment of Biomedical Laboratory Sciences, School of Health Sciences, College of Medicine and Health Sciences, University of Rwanda, Kigali, 3286, Rwanda.ORCID 0000-0002-5569-7090
Elizabeth GoriDepartment of Medical Biochemistry, Molecular Biology and Genetics, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Kigali, 3286, Rwanda.ORCID 0000-0003-3489-7082
Cuthbert MusarurwaDepartment of Biomedical Laboratory Sciences, School of Health Sciences, College of Medicine and Health Sciences, University of Rwanda, Kigali, 3286, Rwanda.ORCID 0000-0001-8248-427X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dyslipidemia, a risk factor for cardiovascular disease (CVD), is common among people living with the human immunodeficiency virus (HIV). The interaction between HIV, dolutegravir (DTG)- based antiretroviral therapy (ART), and lifestyle factors contribute to dyslipidemia, increasing CVD risk. Rwanda has made significant progress in expanding access to ART, achieving high coverage and viral suppression rates. However, comprehensive data on dyslipidemia among people living with HIV (PLWH) in Rwanda is lacking. Therefore, this study aimed to fill this gap by examining the prevalence, types, and correlates of dyslipidemia among PLWH. Methods: This cross-sectional study with 264 participants analyzed serum lipid profiles to estimate the prevalence of dyslipidemia and specific lipid abnormalities. Demographic and lifestyle factors were collected using a questionnaire. Differences in categorical variables between HIV-positive and HIV-negative groups were assessed using chi-square or Fisher's exact tests. Continuous variables were compared using the Wilcoxon rank-sum test. Multivariable logistic regression models, stratified by HIV status, identified factors independently associated with dyslipidemia, reported as adjusted odds ratios (aOR) and 95% confidence intervals (CI). Statistical significance was defined as p-value < 0.05. Results: Dyslipidemia (NCEP ATP III criteria) was present in 74.2% of participants, significantly higher among PLWH (82.7%) than HIV-negative group (59.4%). Hypoalphalipoproteinemia and hyperbetalipoproteinemia were more common in PLWH (72.6% and 53.0%) vs HIV-negative (57.3% and 3.1%). Male gender reduced odds of dyslipidemia in both groups; smoking significantly increased risk among PLWH (aOR 8.8; 95% CI 1.73-44.59), while alcohol consumption was protective (aOR 0.2; 95% CI 0.07-0.55). DTG- based ART duration > 6-12 months increased odds of dyslipidemia vs ≤ 6 months (aOR 4.8; 95% CI 1.11-20.93). Conclusion: The study found a high prevalence of dyslipidemia among PLWH on ART, linked to ART duration, age, smoking and sex, highlighting the need for regular screening, lifestyle interventions, and tailored HIV care.

Indexed as

antiretroviral therapycardiovascular diseases riskdolutegravirdyslipidemiaHIVlipid profiles

Identifiers

PMID40688242
PMCPMC12275987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.